Eaton Vance Worldwide Health Sciences Fund recently disclosed its N-PORT filing for the second quarter of 2025, unveiling its strategic investment moves during this period. The fund, specializing in the healthcare sector, invests globally in companies driving scientific advancements in healthcare, including biotechnology, pharmaceuticals, diagnostics, and medical equipment. Managed from Boston and London, the fund adopts a strategy centered on acquiring stocks that are reasonably priced relative to their intrinsic value, with a focus on long-term growth. The fund’s managers carefully evaluate factors such as market share potential and research and development outlooks in their stock selection process.
In the second quarter of 2025, Eaton Vance Worldwide Health Sciences Fund made significant additions to its portfolio. The standout addition was Elevance Health Inc (NYSE:ELV), with 34,372 shares, constituting 1.54% of the portfolio and valued at $13.19 million. The fund also added Medtronic PLC (NYSE:MDT) with 157,694 shares worth $13.08 million, and Centessa Pharmaceuticals PLC (NASDAQ:CNTA) with 146,529 shares valued at $1.98 million.
Moreover, the fund increased its stakes in nine stocks, notably enhancing its position in Stryker Corp (NYSE:SYK) by 115.62% and Straumann Holding AG (XSWX:STMN) by 33.46%. On the other hand, the fund completely exited holdings in five companies, including SPDR Biotech ETF (XBI) and Sartorius AG (XTER:SRT3).
Additionally, Eaton Vance Worldwide Health Sciences Fund reduced its position in 12 stocks, with significant reductions in Thermo Fisher Scientific Inc (NYSE:TMO) and Humana Inc (NYSE:HUM). As of Q2 2025, the fund’s portfolio comprised 44 stocks, with top holdings in Eli Lilly and Co, AbbVie Inc, AstraZeneca PLC, Abbott Laboratories, and Roche Holding AG. The fund’s focus remains on the healthcare industry, emphasizing long-term growth and fundamental value.
Please note that this analysis, sourced from GuruFocus, offers general insights based on historical data and analyst projections. It does not provide personalized financial advice or recommendations for specific investment decisions. The aim is to present data-driven analysis for informed investment considerations, without considering individual circumstances or objectives. For the latest company updates or qualitative information, investors are advised to conduct their research. GuruFocus has no positions in the mentioned stocks.
Tags: biotechnology
Read more from finance.yahoo.com